Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“One of the main point of discussion at this ESMO is PFS2 vs OS in breast cancer trials.
After ODAC vote of 6- 3 for serena -6 , this has become main issue for discussion. Final result of CAPItello trial also showed PFS2 gain, but no OS gain.
So tell me what do u think? Is PFS2 enough or we need OS for breast cancer trials?
Do vote on Poll below on X․”
